TMEM38A: A TMEM Family Transmembrane Protein as A Drug Target Or Biomarker

Target Name: TMEM38A

NCBI ID: G79041

TMEM38A

TMEM38A: A TMEM Family Transmembrane Protein as A Drug Target Or Biomarker

TMEM38A (MGC3169) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the transmembrane protein family, which means that it spans the cell membrane and is involved in various cellular processes. One of the most interesting aspects of TMEM38A is its potential as a drug target or biomarker.

TMEM38A has been shown to play a role in a variety of biological processes, including cell signaling, cell adhesion, and neurotransmitter release. It is also involved in the regulation of inflammation and immune response. These roles make TMEM38A an attractive target for drug development, as researchers can use it as a therapeutic agent to treat a variety of diseases.

One of the key challenges in studying TMEM38A as a drug target is its complex structure. TMEM38A is a transmembrane protein that spans the cell membrane and consists of multiple domains, including an extracellular domain, a transmembrane domain, and an intracellular domain. The transmembrane domain is the region of the protein that is involved in its functions, such as cell signaling and neurotransmitter release.

The transmembrane domain of TMEM38A is composed of four conserved domains: a transmembrane region, a cytoplasmic region, a variable region, and a cytoplasmic tail. The transmembrane region is the most well-studied, and it is involved in the formation ofTMEM38A's channels, which are involved in the transfer of molecules across the cell membrane. The cytoplasmic region is involved in the regulation ofTMEM38A's stability and is thought to play a role in its degradation. The variable region is involved in the regulation ofTMEM38A's activity, and the cytoplasmic tail is involved in the regulation ofTMEM38A's stability and is thought to play a role in its degradation.

TMEM38A has also been shown to play a role in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. TMEM38A is involved in the regulation of cell adhesion by controlling the formation of tight junctions, which are a type of cell-cell adhesion structure. These observations make TMEM38A an attractive target for drugs that are designed to modulate cell adhesion, such as those used to treat cancer.

In addition to its role in cell signaling and adhesion, TMEM38A is also involved in the regulation of neurotransmitter release. Neurotransmitters are the chemical messengers that are used by the brain to communicate with other cells. TMEM38A is involved in the regulation of neurotransmitter release by controlling the release of vesicles from the axon terminal of neurons. This makes TMEM38A an attractive target for drugs that are designed to treat neurodegenerative diseases, such as Alzheimer's disease.

Another potential role for TMEM38A is in the regulation of inflammation and immune response. TMEM38A is involved in the regulation of inflammation by controlling the production of pro-inflammatory cytokines. It is also involved in the regulation of immune response by controlling the production of T cells, which are a type of immune cell that play a critical role in defending against infection. These observations make TMEM38A an attractive target for drugs that are designed to treat inflammatory and immune-related diseases.

In conclusion, TMEM38A is a protein that is involved in a variety of biological processes, including cell signaling, cell adhesion, neurotransmitter release, and inflammation

Protein Name: Transmembrane Protein 38A

Functions: Monovalent cation channel required for maintenance of rapid intracellular calcium release. May act as a potassium counter-ion channel that functions in synchronization with calcium release from intracellular stores

The "TMEM38A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM38A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets